Celcuity's (CELC) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Celcuity (NASDAQ:CELC - Free Report) in a research report released on Tuesday morning,Benzinga reports. The firm currently has a $29.00 price objective on the stock.

Separately, HC Wainwright restated a "buy" rating and set a $27.00 price objective on shares of Celcuity in a research report on Tuesday. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Celcuity presently has an average rating of "Buy" and a consensus target price of $30.17.

Celcuity Price Performance

Shares of Celcuity stock traded down $0.20 on Tuesday, hitting $8.65. The company's stock had a trading volume of 502,142 shares, compared to its average volume of 294,085. The company has a market capitalization of $321.17 million, a price-to-earnings ratio of -3.31 and a beta of 0.44. Celcuity has a 1 year low of $7.70 and a 1 year high of $20.15. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The firm has a fifty day moving average price of $10.99 and a 200-day moving average price of $12.77.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.13). As a group, sell-side analysts anticipate that Celcuity will post -2.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its position in shares of Celcuity by 2,083.4% in the third quarter. BNP Paribas Financial Markets now owns 45,110 shares of the company's stock valued at $673,000 after buying an additional 43,044 shares during the last quarter. Geode Capital Management LLC grew its holdings in Celcuity by 27.6% in the 3rd quarter. Geode Capital Management LLC now owns 630,369 shares of the company's stock valued at $9,401,000 after buying an additional 136,518 shares in the last quarter. State Street Corp increased its stake in shares of Celcuity by 152.2% in the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company's stock worth $16,512,000 after acquiring an additional 668,318 shares during the last quarter. Barclays PLC raised its holdings in shares of Celcuity by 567.6% during the 3rd quarter. Barclays PLC now owns 53,605 shares of the company's stock worth $800,000 after acquiring an additional 45,576 shares during the period. Finally, Bleakley Financial Group LLC acquired a new position in shares of Celcuity during the 4th quarter valued at about $146,000. Hedge funds and other institutional investors own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.